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Chapter 32 
Liver Transplantation in the Treatment 
of Liver Cancer 
SHUNZABURO IWATSUKI 1 and THOMAS E. STARZL 
The treatment of choice for hepatic malignancy 
has been total surgical removal of tumor(s). Ex-
tensive liver resect..ion such as right and left triseg-
mentectomies can now be performed with an 
operative mortality ofless than 5% [I). Five-year 
survival of primary liver malignancy after suh-
total liver resection has heen as high as 46% [I]. 
On the other hand, the prognosis of liver cancer 
which cannot be treated with the conventional 
technique of subtotal liver resection because of 
extensive hepatic involvement of tumors or co-
existing nonneoplastic liver disorders has been 
quite poor. Total hepatectomy with hepatic re-
placement (orthotopic liver transplantation) is, 
at least in concept, an ideal approach for the 
"unresectable" liver cancer. 
The world's first attempt to treat "unresect-
able" liver cancer by total hepatectomy with he-
patic replacement was made in Denver on May 
5,1963. The patient was a 48-year-old man with 
hepatocellular carcinoma in a cirrhotic liver. He 
died 22 days after transplant from pulmonary 
emboli and sepsis. The postmortem examination 
did not reveal any residual tumors. The first 
patient to live more than I year after liver trans-
plantation also had hepatocellular carcinoma. 
This I-year 7-month-old girl was the eighth re-
cipient in Denver and lived 400 days after trans-
plantation on July 23, 1967. Her tumor first re-
curred in the lungs 3 months after transplant and 
then disseminated into the liver homograft. other 
abdominal organs, and the brain. Despite ..---
efforts to control the tumor by chemotherapy, 
radiation therapy, and surgical debulking proce-
dure, she died from carcinomatosis on August 
26, 1968. These early two cases clearly illustrated 
the issues involved in liver transplantation for 
hepatic malignancies. By-the time the early Den-
ver experience in liver transplantation was re-
ported in the monograph in ) 969 [2], the en-
thusiasm for treating so-called unresectable liver 
cancer with orthotopic liver transplantation had 
been dampened because of the high incidence of 
aggressive tumor recurrence after pOlentially 
curative total hepatectomy with liver replace-
ment. Nevertheless, the treatment of malignant 
tumors by liver transplantation has continued 
because of: () the lack of other effective therapy; 
(2) rare examples of cure of malignancy by total 
hepatectomy with hepatic replacement; and (3) 
the improved overall survival after liver trans-
- -
recent years. f 
The Denver-Pittsburgh experience in ortho-
topic transplantation in the presence of primary 
hepatic malignancy during the last 23 years from 
March 1963 to March 191\6 will be summarized 
in this chapter. There have been several publi-
cations on this subject, reporting individual re-
sults in detail by the OT code numbers of the 
patients for interested readers to review [2-7]. 
Prof. CaIne has provided a similar detailed ac-
count of his experience in England [8]. 
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1 Selection of candidates 
There are two different situations where patients 
who have primary hepatic malignancies require 
total hepatectomy with hepatic replacement (or-
thotopic liver transplantation). In the first, liver 
transplantation is needed primarily because of 
end stage nonmalignant liver disease, but_l!S.oin-
cidental primary hepatic malignancy j{ldentified '_'7!- - ,'. 
either before transplantation or after examina-
tion of the excised liver. Such tumors could have 
been totally removed by subtotal hepatectomy if 
) ~gKKKKE~ the live~Kr~ RMSO seriously diseased. Here, the 
selection of candidates is essentially the same as 
that of candidates with nonmalignant disease. 
In the second situation," liver transplanta-
tion is needed because of a hepatic malignancy 
which cannot be removed by conventional tech-
niques of subtotal hepatectomy. In such patients, 
an extensive search for extrahepatic metastases 
must be carried out before the patient is accepted 
as a candidate. Tumor metastases are investi-
gated with chest X-ray, bone survey, CT scan of 
the chest, abdomen, and brain, bone marrow 
examination, and other sophisticated modern 
diagnostic procedures. A history of slow growth, 
16 good response to chemotherapy or radiation 
therapy, and of known favorable histology may 
also play an important role in selecting a candi-
date. A final decision for or against hepatic re-
placement is often made after a donor liver graft 
becomes available, at which time definitive ex-
ploration is carried out. If a tumor is found out-
side the liver, long-term survival of the patient is 
so unlikely that the attempt usually is abandoned 
and the liver is given to a "backup" candidate. 
The differentiation of primary hepatic malig-
nancies (particularly cholangiocarcinoma) from 
liver metastases can be extremely difficult, even 
with adequate biopsy material for histological 
examination. There have been only a handful of 
examples of liver transplantation for metastatic 
liver tumors [2,8,9]. In general, patients with 
metastatic liver malignancies are not suitable 
candidates for liver transplantation, at least at 
the present time. However, there may be occa-
sional patients who develop metastases only in 
the liver, years after complete local control of 
carcinomas orcarcinoids of the intestinal tract. It 
is possible, but not proven, that such rare pa-
tients with metastatic liver disease can benefit by 
orthotopic liver transplantation. 
2 Histological considerations 
Hepatocellular carcinoma is the most common 
primary hepatic malignancy. It can develop 
in the normal liver. Many such tumors can 
be treated by subtotal hepatectomy. In many 
others, extrahepatic metastases have already de-
veloped by the time the diagnosis is made. Since 
hepatocellular carcinoma tends to metastasize 
relatively early in its clinical course, it is uncom-
mon to find the disease in a stage where subtotal 
~~::::f-K~~_ .... ~D-"dD} rr\..Juau UuL Cit: \...UJdL.'''C;, th.U. 'W'tUCJt; 
total hepatectomy would be. '''''''''''--<..-4 ,S . 
In contas1. hepatocellular carcinomas in livers 
affected with some other disease may be much 
less advanced but not treatable by partial hepa-
tectomy because oT impaired hepatic function. 
Total hepatectomy with liv~r replacement may 
be the ideal treatment in such cases in which the 
primary diagnosis is macronodular or micronod-
ular cirrhosis (posthepatitic cirrhosis, Laennec's 
cirrhosis), tyrosinemia, hemochromatosis, bili-
ary atresia, Thorotrast liver disease, and other 
advanced liver diseases. Orthotopic liver trans-
plantation has been effective in treating such 
coincidental hepatocellular carcinomas. 
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Although it develops in the normal liver. fi-
brolamellar carcinoma carries a beller prognosis 
than other hepatocellular carcinomas. This tu-
mor is a histological suhtypeof hepatocellular 
carcinoma and is composed or large polygonal 
eosinophilic cells dispersed throughout a fibro-
lamellar stroma. It is characterized by its pre-
valence in young patients, its indolent growth, 
and an increased resectability rate and survival in 
comparison with other types of hepatocellular 
carcinoma [10-14]. Because metastases ~te 
in its clinical course, fibrolamellar carcinomas 
which cannot be resected (even by the most ex-
tensive subtotal hepatectomy. such as right or 
left trisegmentectomy) may be treated effectively 
by total hepatectomy and replacement. 
Cholangiocarcinoma is the second most com-
mon primary hepatic malignancy. It usua\1y 
arises in the normal liver and, like hepatocel-
lular carcinoma, it metastasizes relatively early in 
its course. Therefore, it is rare to find this tumor 
in a stage suitable for liver transplantation. 
Hepatoblastoma is the most common hepatic 
malignahcy in early childhood. It grows rapidly 
and spreads outside the liver early in its clinical 
course. It is rare ror hepatoblastoma to be effec-
tively treated by liver transplantation, unless the 
tumor has been under good chemotherapeutic 
control. 
There are other unusual primary hepatic ma-
lignancies, such as hem!)ngiosarcoma, rhabdo-
myosarcoma, and leiomyosarcoma. These sar-
comas, like hepatoblastoma, grow rapidly and 
metastasize early. It is exceptional that these 
sarcomas can be effectively treated by liver 
transplantation. 
Although classified as sarcomas, q lithelioid 
hemangioendotheliomas or epithelioid heman-
gioendothelial sarcomas of the liver possess dis-
tinct clinical and pathological features. This type 
of tumor was originally described as intravas-
cular bronchioloalveolar tumor (IVBAT) of the 
lung by Dail and Liebow in 1975 [J 5]. The angio-
genic nature of IVBA T was subsequently con-
firmed by light-microscopic and ultrastructural 
observations. Factor VIII-related antigen, an en-
dothelial cell marker, was first identified in tu-
mor cells ofJVBAT by Weldon-Linne et al. [J 6]. 
In 1982, the term "epithelioid hemangioendo-
thelioma" was proposed by Weiss and Enzinger 
[17]. Involvement of the liver was first thought to 
be metastatic from IVBA T of the lung or its soft 
tissue counterpart, but later it was confirmed 
that this tumor can originate in the liver as well. 
Ishak et al. [18] reported 32 cases or epithelioid 
hemangioendothelioma of the liver in 1984. The 
clinical course of this tumor is between that of 
hemangioma and conventional angiosarcoma. 
Nine or the 32 patients in this report survived 5 
years or longer regardless of the treatment, but 
the same number of patients developed meta-
stases during follow-up. This tumor may be effec-
I 
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placement when cqnventional techniques of sub-
total hepatectomy cannot be applied. 
A carcinoma arising from the june tion of the 
right and left hepatic ducts is called Klatskin's 
tumor. Because or the location, signs of >')b'struc-
tive jaundice appear when the tumor is still small, 
usually less than a few centimeters in diameter, 
and the diagnosis of malignancy can be made 
relatively early. This tu·mor usually grows slowly 
and metastasizes late in its clinical course. It ca n 
often be resected, with or without partial hepa· 
tectomy, and the bile duct can be reconstructed. 
However, in many cases, the tumor is located too 
high in the liver tissue and complete resection is 
(G344) 
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not possible. In such patients, the bile duct can be 
intubated surgically or under radiological con-
trol to relieve obstructive jaundice, followed by 
radiation therapy. This palliative measure has 
been successful both in prolonging life and in 
improving the quality of life for 1-2 years on 
average [19]. Although this Klatskin's tumor 
would appear to be an, excellent indication for 
orthotopic liver transplantation because of its 
small size, slow growth, and relatively late meta-
stasis, the survival after transplantation has been 
disappointing and not significantly better than 
that after palliative procedures, as will be dis-
cussed later in this chapter. 
3 Denver-Pittsburgh experience with 
transplantation 
During the 23-year period from March 1963 to 
March 1986, 750 patients received orthotopic 
liver transplantation at the University Health 
Sciences Center of Colorado (1963-1980) and 
the University Health Center of Pittsburgh 
(\981-1986). The first 170 patients were treated 
by azathioprine and steroids with or without 
antilymphocyte globulin, and the following 
580 patients were treated by cyc\osporine and 
steroids with or without monoclonal anti-T-
lymphocyte antibody. Of the 750 patients, 63 
(8.4%) had transplantation in the presence of a 
primary hepatic malignancy. For analysis, the 63 
patients were divided into two groups. 
Group I consisted of 14 patients who had liver 
replacement primarily to treat an end stage non-
malignant liver disease, but who were found to 
have a coincidental primary hepatic malignancy 
either before transplantation or after examina-
tion of the excised whole liver. The tumor could 
have been totally removed by the conventional 
technique of partial hepatectomy if the liver had 
not been so seriously diseased. 
Group 2 consisted of 49 patients whose sole or 
principal reason for liver replacement was a ma-
lignancy which could not be removed by partial 
hepatectomy. The patients in both groups I and 
2 were further classified according to whether 
iml: i unosuppression was with azathioprine and 
corticosteroids (subgroup A) or cyclosporine 
and corticosteroids (subgroup B). 
3.1 Histological diagnosis 
The histological diagnoses of 63 primary liver 
malignancies treated with orthotopic liver trans-
plantation are listed in Table 32.1. There were 
42 hepatocellular carcinomas (HCCs), of which 
nine were of the fibrolamellar variant. The other 
tumors were ten bile duct carcinomas (Klatskin's 
tumors), five epithelioid hemangioendothelio-
. tI~l"~~;"r""rinomasK and one each of 
hepa!Cl!!:t~ltellKa .. -i:1g}glr~u I \,;Uu.aa, 'h",l-:;Uo\"'a. "",, .. iVthQ 
of unknown primary site, and epithelioid tumor 
of undetermi ned' histology. 
Of the 14 primary liver malignancies in group 
J (coincidental tumors), 13 were HCCs and one 
was a hepatoblastoma. These coincidental hepa-
tic malignancies were found iT! tyrosinemia (four 
cases), biliary atresia (three cases), aJpha- 1-
antitrypsin deficiency disease (two cases), post-
hepatitic cirrhosis (two cases), Laennec's cir-
rhosis (one case), Neville's disease (one case), 
and familial cholestatic syndrome (one case). 
(G345) 
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Of the 49 primary liver malignancies in group 
2 (unresectablc tumors), 14 developed in livers 
that had underlying serious hepatic diseases. Six 
HCCs were in livers that had postnecrotic cir-
rhosis. The underlying disease in two cases was 
tyrosinemia, and in one case each the diagnoses 
were Thorotrast liver and biliary atresia. Three 
patients with bile duct carcinoma (Klatskin's 
tumor) had sclerosing cholangitis. One case of 
cholangiocarcinoma had developed against a 
background of postnecrotic cirrhosis. The re-
maining 35 malignancies had developed in an 
apparently normal liver. 
3.2 Residual tumor 
No patient with primary liver malignancy who 
underwent liver transplantation was known pre-
operatively to have had extrahepatic involve-
ment. However, five patients of group 2 (unre-
sectable tumor) were found to have metastases 
at the time of transplantation. One patient with 
epithelioid hemangioendothelioma had fine 
metastases to the lung and peritoneum. This 
patient is still alive and well without any sign 
of tumor regrowth more than 9 years later. 
The second patient with hemangiosarcoma had 
metastases to the lungs and the omentum at the 
time of emergency transplantation for intra-
abdominal bleeding, which was thought to be 
from ruptured multiple hemangiomas. When 
this patient died 3 months after operation as a 
result of pneumonia and liver graft failure, the 
autopsy also revealed metastases to the bone 
marrow. The third patient had adenocarcinoma 
of unknown prim~ site and was found to have 
metastases to~abdominallymph nodes dur-
ing surgery; some were not removed. This patient 
developed radiological evidence of bone meta-
stases at II months but is still alive with a tumor 
15 months after transplantation. The fourth pa-
tient with fibrolamellar HCC had tumor invasion 
of the diaphragm. Microscopic examination of 
the excised whole liver also revealed tumor-
positive hilar lymph nodes. This patient died 1 
month after transplantation from liver failure 
and infectious complications. The autopsy re-
vealed no residual fibrolamellar HCC, but there 
was an incidental small adenocarcinoma of the 
lung. The fifth patient had bile duct carcinoma 
and primary sclerosing cholangitis. Several re-
gionallymph nodes were involved at the time of 
surgery. This patient is alive without evidence of 
tumor regrowth 3 months after transplantation. 
Eleven other patients in group 2 (un resectable 
tumor) died within 2 months from various com-
plications ofliver transplantation. Preoperatively 
and at the time of operation, all II were thought 
to be free of extrahepatic tumor. At autopsy, 
only one had gross or mkl'os{'l)ryir ""in"n"p, (lr 
only 5 days after liver transplantation, had meta-
static cholangiocarcinoma in the lungs, vertebrae, 
kidneys, and some abdominal lymph nodes. The 
remaining ten patients were free of tumor insofar 
as this could be determined from complete post-
mortem examination, indicating that screening 
for candidacy had been grossly llccurate in the 
great majority of cases" 
(G346) 
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3.3 Tumor recurrence 
3.3.1 Incidental malignancies 
In group I, there have been no tumor recurrences 
among the 14 patients whose excised liver con-
tained incidental primary liver malignancies. 
Thirteen patients had HCC and one had hcpa-
toblastoma. Two patients died after liver trans-
plantation-one on the 1st postoperative day 
from hyperkalemia and the other almost 2 years 
after the operation from lung cancer. The re-
maining 12 patients are alive and free of tumor 
recurrence from 3 months to more than 16 years 
after liver transplantation (median 24 months). 
3.3.2 Unresectable malignancies 
In group 2, 36 of 49 patients whose main reason 
for liver transplantation was primary liver malig-
nancy survived for at least 3 months after trans-
plantation and thus became suitable for mean-
ingful observations with respect to recurrence. 
The 36 patients included four of the five who 
were found at the time of transplantation to have 
extrahepatic involvement as described in the pre-
ceding section. The other 32 were all considered 
to have had a gross tumor removed by total 
hepa tectom y. 
In 20 (63%) of the 32 patients who were made 
potentially tumor-free by liver transplantation, 
the original tumor recurred after I -42 months 
(median 9 months). HCC that was not fibrola-
mellar in type recurred in 8 (62%) of 13 patients, 
all within I year (median 4 months; Table 32.2).· 
Recurrence of fibrolarnellar HCC was also seen 
in five (71 %) of seven patients (Table 32.2), but 
all after 1 year (median 16 months). Four of the 
seven bile duct carcinomas recurred, two before 
and two after I year; the exceptional patient who 
did not have a recurrence died of other causes 3 
months after operation. Two of the four epitheli-
oid hemangioendotheliomas recurred within I 
year. One patient with cholangiocarcinoma de-
veloped a tumor recurrence in the 15th post-
operative month. One-year tumor-free rates are 
also shown in Tahle 32.2. 
3.4 Location of recurrences 
The first location of tumor recurrence and the 
organs ultimately involved by tumors were 
examined in the 20 patients of group 2 who ren-
dered potentially tumor-free at the time of trans-
plantation but who later developed metastases. 
The grafted liver and the lung were the two 
organs most commonly affected by tumro recur-
--= rences (Table 32.3). 
The liver was the first site of recurrence in eight 
patients, the lung in six patients, both the liver 
and the lung simultaneously in two patients, the 
bone in two patients, and the skin and the pelvic 
peritoneum in one patient each. 
The liver was ultimately involved by recurrent 
tumors in 12 patients. Other locations within the 
abdomen, such as the abdominal lymph nodes 
and the peritoneum, were affected in 13 patients. 
'"rh ..... ,.- ..... L..""r,.. ...... J.= r ;-"D-D·i~KKt~" 11 np_ 
ttents, an:..! tne o~ a~n lUl(' vunc Ifl dlree pauents 
each. 
3.5 Patient survival 
The overall survivals tlner liver transpla'ntation 
have greatly improved since the introduction of 
cyclosporine-steroid therapy in' March 1980 [6]. 
Since that time, the survival rate at I year after 
operation and each year thereafter for at least 5 
years has more than doubled compared with that 
previously obtained with azathioprine and steroid 
therapy (Fig. 32.1). The actuarial 5-year survival 
in a1\ patients treated since 1980 is slightly better 
than 60%. 
(G347) 
3.5.1 Survival of patients with group 1 tumors 
or the 14 patients who had incidental hepatic 
malignancies, 12 are still alive and free of tumor 
from 3 months to 16 years after operation. Two 
patients died after transplantation. One patient 
with biliary atresia and an incidental HCC 
died on the 1 st postoperative day from hyper-
kalemia. Another patient with a micronodular 
(Laennec's) cirrhosis and incidental HCC died 23 
months after transplantation from disseminated 
oat cell cancer of the lung, which was discovered 
16 months after transplantation. Actuarial sur-
vival curves of patients with incidental primary 
liver malignancy are shown in Fig. 32.2. 
3.5.2 Survival of patients with group 2 tumors 
(unresectable tumors) 
or the 20 patients of subgroup A who were 
treated with azathioprine and steroids, 13 (65%) 
had died by the end of the first 6 months. At the 
end of the year, only six (30%) remained alive, of 
whom all but one have subsequently died (Fig. 
32.3). The single survivor, now 9t years after 
transplantation, had epithelioid hemangioendo-
thelioma with peritoneal and pulmonary meta-
stases at the time of transplantation. 
The patients of subgroup B who were treated 
with cyclosporine and steroids had greatly im-
proved early postoperative results with a 6-
month actuarial survival of 80%. This reflected 
the better overall prognosis for early recovery 
using cyclosporine-steroid therapy. However, 
after the half-year mark, survival continued to 
decline, primarily because of the recurrent ma-
lignancies, as will be described in the following 
sections. The actuarial 1- and 3-year survivals of 
patients with unresectable tumors after liver 
transplantation with cyc1osporine-steroid ther-
apy (group 2B) are projected at 58% and 24%, 
respectively (Fig. 32.3). As of April 1986, only 
12 (41 %) of the original 29 recipients in group 
2B are still alive after 2 months to 41 years. Three 
of the surviving patients at 2, 3, and 13 months, 
respectively, had tumor-positive regional lymph 
nodes at the time of transplantation, and five 
others are living with known recurrences. 
3.6 Main causes of deaths in group 2 
Of the 49 patients whose principal reason for 
liver transplantation was the presence of unre-
sectable primary liver malignancy (group 2), 36 
had died before April 10, 1986. Of the 36 deaths, 
26 were within I year after transplantation. 
Seven of the 26 deaths were due to nonneoplastic 
complications such as liver graft failure of infec-
tions or both: The majority of these nonneoplastic 
deaths occurred among the patients transplanted 
before 1970 [2-7J. Of the ten deaths that oc-
curred a year or n;g.r.e-after transplantation, nine 
were directly ~y tumor recurrence. Thus, 
the shape of the survival curves both before and 
nated from thf' 6th mon')' onward by the fatal 
effects of tumor recurrence (Fig. 32.3). 
3.7 Histology, recurrence, and survival in 
group 2 
Of the eight patients with fibrolamellar HCC, 
two died of nonneoplastic transplant complica-
tions in the 2nd and 7th months without any 
evidence of residual or recurrent tumors. The 
remaining six patients lived for at least I year. 
These six I-year survivors were thought to be free 
of tumor when they passed the 12-month mark. 
However, metastases subsequently developed in 
four of the six patients, two of whom died 21 and 
(G348) 
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36 months after operation. The other two are 
living with known metastases after more than 2 
and 4 years. A fifth patient died from liver graft 
failure and infectious complications just less than 
3 years after operation. The sixth patient is alive, 
free of tumor recurrence more than 4 years after 
transplantation. 
In contrast, patients with nonfibrolamellar 
Bee had earlier and more lethal metastases. Of 
21 such patients, eight died within 3 months, too 
soon to allow meaningful evaluation for recur-
rence. Of the II patients with a longer follow-up, 
eight developed a recurrent tumor within a year 
and subsequently died from tumor recurrence 
within 18 months after transplantation; two 
more patients died from nonneoplastic causes 3 
and 6 months after transplantation. As of April 
1986, only three patients are a live and free of 
tumor recurrence 3, II, and 27 months after 
transplantation; the follow-ups of two of these 
three are too short to be meaningful. Thus, the 
conventional Bees carried a far poorer prog-
nosis than the fibrolamellar variant. 
Of the ten patients with bile duct cancer 
(Klatskin's tumor), four died from nonneoplas-
tic causes within 3 months after transplantation. 
Two patients died directly from recurrent tumors 
within a year, and two others developed tumor 
recurrences after a year and died from recurrent 
malignancy 25 and 54 months after liver trans-
plantation. Two others who are alive and free 
of tumor after 3 and 6 months have too short 
a foIJow-up to be considered. 
Of the five patients with epithelioid hem-
angioendothelioma, two developed recurrent 
tumors 2 and I] months after transplantation 
and died directly from a recurrent tumor 3 and 
16 months after transplantation, respectively. 
Three others are alive and free of tumor more 
than 6 months, 2 years, and 9 years after 
transplantation. 
Of the five patients with other primary liver 
malignancies, two lived more than a year. One 
with cholangiocarcinoma developed tumor re-
currence 15 months after transplantation and 
died directly from a recurrent tumor 5 months 
afterward. Another with adenocarcinoma of un-
known primary site developed a recurrence 11 
months after transplantation, but he is alive 
more than 5 months later. 
4 Past reflections and future prospects 
Remarkable progress has been made in the field 
of organ transplantation since the introduction 
ofeyclosporine in the late 1 970s. More than 70% 
ofliver recipients now survive at least a year after 
operation, and approximately 60% overall are 
expected to live for 5 years after liver transplan-
tation. However, the survival of patients who 
received liver transplantation because of unre-
Sectable primary hepatic malignancies has been 
poor and less than a Quarter of these nl!tifDnt~ ""ill 
-' ~~K~~ _ •• _ .. u",,",J uc1u::tl.HClJlldUUJi t>/en 
w;th cyclosponn.; therapy. '[,wo-th:rds of the pa-
tients developed tumor recurrence even though 
they were thought to have been rendered tumor-
free after total hepatectomy. Recurrent tumors 
were the most frequetlt cause of death among 
these patients, and nearly all of the deaths after a 
year were directly caused by ~r attributed to 
recurrent neoplasms. 
The high recurrence rate after liver transplan-
tation for un resectable tumors reflects in part the 
advanced defvelopment of the neoplasms by the 
time a decision was made to attempt therapy 
with transplantation. However, the immunosup-
pression necessa ry to prevent graft rejection 
(G349) 
might actually have expedited the growth of re-
sidual nests of malignant cells left after the total 
hepatectomy, as was suggested a number of years 
ago [2] and has since been supported by many 
recent investigations of host factors promoting 
tumor metastases [20- 22]. 
The tendency of the metastases from hepatic 
malignancies to recur in the liver grafts is of 
particular interest in reflecting on the mechan-
isms of tumor metastasis. One possible explana-
tion is that the malignant cells of primary hepa-
tic tumors may find the best microenvironment 
to be in the liver itself. Another explanation 
could be that the grafted liver, which is itself 
under constant attack from the host immune 
system, may provide the location of the weakest 
antitumor defense where circulating neoplastic 
cells can nest and grow. Further investigations 
are needed to explain this peculiar and dangerous 
phenomenon. 
Of all the tumors with which experience has 
been accumulated so far, fibrolamellar HCC has 
emerged as the best for trea tment with trans-
plantation. This tumor is known to behave less 
aggressively than. most other malignant hepatic 
neoplasms [10- 14]. Allhough it recurred in more 
than half the patients after transplantation, the 
metastases tended to appear late and to grow 
relatively slowly. Two of our patients with recur-
rence have been in good condition for more than 
I and 3 years after multiple pulmonary meta-
stases were first proved. 
Epithelioid hemangioendothelioma is a pe-
culiar malignant neoplasm which can originate 
in the lung, soft tissue, and liver [15-18]. Our 
experience in this tumor has been mixed with ag-
gressive recurrences and potential cures. Two of 
the five patients died from aggressive recurrent 
tumors. The remaining three, including one with 
distant metastases at the time of transplantation, 
are alive and well without any clinical evidence of 
tumor more than 6 months, 2 years, and 9 years 
after transplantation. 
With all other kinds of tumor, metastases 
tended to appear early and led to death prompt-
ly. The prognosis with nonfibrolamellar HCC 
has been very poor. None of our patients with 
proximal duct cell carcinomas (Klatskin's tu-
mors) have lived 5 years and, to our knowledge, 
this has not been accomplished in any other 
center [8,23]. 
It is sometimes tempting during the acqui-
sition of this experience to conclude that liver 
transplantation for malignant hepatic malig-
v;, >' . , IK~ nancy is conceptually unsound,\J.!\Jiprffnrcoinci-
dental malignancies and probably for fibrolamel-
lar HCC, and to abandon such efforts. However, 
the most encouraging aspect of this experience 
was the almost uniform survival of patients with 
coincidental hepatic malignancy. The fact that 
none of these patients developed a recurrence 
during the follow-up proved that the mere pre-
sence ofa hepatic maljlD!D1~n~s j" l"I()t,,, "~"IIIlIIt .. 
",UIHfi:UnJICallOn h)r live transplantatIOn. 
Even in the patients \)f group 2, arrest and 
control of the malignant process have been ac-
complished under some of the least likely circum-
stances, as with the patient who had distant 
metastases at the time of transplantation from 
hepatic epithelioid hemangioendothelioma and a 
patient with nonfibrolamellar ·HCC. There has 
been no identifiable reason why some patients 
were spared recurrence and why others were not. 
The poor results so far have made it clear that 
liver transplantation for unresectable cancer will 
have to be tied to some other kind of therapeutic 
effort in future trials. The usual approach of 
giving adjuvant chemotherapy or radiation 
therapy will not be sufficient to prevent tumor 
(G350) 
recurrence for a long time as was experienced in 
two of our four recent patients who developed 
aggressive recurrences of nonfibrolamellar HCC 
within a few months in spite of prophylactic 
treatment with adriamycin and other chemothe-
rapeutic agents. Huber et al. [9] have described a 
novel approach in which patients with metastatic 
liver malignancies had liver replacement as well 
as total body irradiation and ultradose chemo-
therapy, followed by autotransplantation of 
stored bone marrow. One of their patients whose 
original disease was a carcinoma of the breast 
was alive, free of tumor, more than 3 years after 
liver transplantation (personal communication). 
Further experiences and more effective adju-
vant therapies are required for liver transplan-
tation to establish a firm role in the treatment of 
hepatic malignancies: 
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Table 32.1. H1SiOlogical QII'gnOS1!> 0(0) pnmary liver 
malignancies 
Group Total 
IA 18 2A 28 
Hepatocellular carcinoma 2 II 13 16 42 
(fibrolamellar type) (I) (I) (7) (9)-
Bile duct cancer 0 0 5 5 10 
(Klatskin's tumor) 
Epithelioid hemangio- 0 0 2 3 5 
endothelioma 
Cholangiocarcinoma 0 0 I I 2 
Hepatoblastoma I 0 0 0 I 
Angiosarcoma 0 0 0 I 1 
Adenocarcinoma of un- O 0 0 1 1 
known primary site 
Epithelioid tumor. histo- 0 0 0 
logy undetennined 
Total 3 II 21 28 63 
Table 32.2. Incidence of tumor recurrence and I-year tumor-free survival among the patients in group 2 who 
survived over 3 months after liver transplant; all gross tumors were removed by total hepatectomy 
Hepatocellular carcinoma 
Nonfibrolamellar 
Fibrolamellar 
Bile duct cancer 
Epithelioid hemangioendothelial sarcoma 
Cholangiocarcinorna 
Total 
Tumor recurrence 
No. 
12/20 
(8/13) 
(4/1) 
4/7 
2/4 
1/1 
20/32 
Percent 
60 
62 
57 
57 
50 
100 
63 
I-year tumor-free 
No. 
7/15 
(1/9) 
(6/6) 
2/4 
1/3 
1/1 
11/23 
Percent 
47 
I I 
100 
50 
33 
100 
48 
(G.T2S) 
Table 32.3. Location of recurrence of original primary 
liver malignancy in 20 patients 
Liver 
Abdomen other than liver" 
Lung 
Bone 
Brain 
Skin 
First Organ 
location of ultimately 
recurrence involved 
10 (2)b 12 
I 13 
8 (2) II 
2 3 
0 3 
I I 
• Abdominal lymph nodes, peritoneum 
b Two patients had recurrences both in the liver and 
the lung discovered simultaneously 
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Fig. 32.1. The survivals I!fter liver transplantation 
have more than doubled since the introduction of 
cyclosporine in .1980 
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Fig_ 32.2. The survivals of patients with incidental 
primary malignancy. Group lA-incidental tumor 
treated by azathioprine and steroids; group J B-
incidental tumor treated by cyc1osporine and steroids 
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Fig. 32.3. The survivals of patients with unresectable 
primary liver malignancy. Group 2A-unresectable 
tumor treated by azathioprine and steroids; group 
2B-unresectable tumor treated by cyclosporine and 
steroids 
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